National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ruxolitinib (Jakavi®) for the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Rapid Review

Commenced Completed Outcome
01 August 2012 10 August 2012 Full pharmacoeconomic evaluation recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
20/12/2012  09/07/2013 Reimbursement not recommended

The NCPE do not consider ruxolitinib to be a cost effective treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Download summary

July 2015

The HSE has approved reimbursement following confidential price negotiations.